Resources from the same session
700O - Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
Presenter: Maxime Meylan
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast
701O - Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
Presenter: Zeynep Zengin
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast
702O - Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
Presenter: Sumanta Pal
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast
LBA25 - Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
Presenter: Yann Vano
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 700O and 701O
Presenter: Walter Berger
Session: Proffered Paper - GU, non prostate 2
Resources:
Slides
Webcast
Invited Discussant 702O and LBA25
Presenter: Laurence Albiges
Session: Proffered Paper - GU, non prostate 2
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Manuela Schmidinger
Session: Proffered Paper - GU, non prostate 2
Resources:
Webcast